Discontinued — last reported Q4 '25
TransDigm Group Interest Paid increased by 255.7% to $658.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 51.3%, from $435.00M to $658.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 10.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $209.00M | $234.00M | $273.00M | $301.00M | $217.00M | $266.00M | $272.00M | $273.00M | $263.00M | $352.00M | $205.00M | $340.00M | $232.00M | $381.00M | $162.00M | $435.00M | $311.00M | $573.00M | $185.00M | $658.00M |
| QoQ Change | — | +12.0% | +16.7% | +10.3% | -27.9% | +22.6% | +2.3% | +0.4% | -3.7% | +33.8% | -41.8% | +65.9% | -31.8% | +64.2% | -57.5% | +168.5% | -28.5% | +84.2% | -67.7% | +255.7% |
| YoY Change | — | — | — | — | +3.8% | +13.7% | -0.4% | -9.3% | +21.2% | +32.3% | -24.6% | +24.5% | -11.8% | +8.2% | -21.0% | +27.9% | +34.1% | +50.4% | +14.2% | +51.3% |